Asabys Partners, member of CataloniaBio & HealthTec, leads and invests in the first round of funding from its new Sabadell Asabys II fund, where Augustine Therapeutics is able to raise a total of 17 million euros. The pharmaceutical company Eli Lilly & Company and the Charcot-Marie-Tooth Research Foundation (CMT) have also participated in this round, as well as existing investors from the company.
The funding will allow Augustine Therapeutics to enter the clinical phase in 2025 with its main program in peripheral axonopathies and advance in the preclinical development of the rest of its portfolio in neurodegenerative and cardiometabolic diseases.
“Augustine molecules are unique, selective and powerful in the differential inhibition of a validated therapeutic target, and with a great impact on a wide variety of indications. Augustine's portfolio of molecules exceeds the known limitations of other inhibitors currently in early clinical development. We are delighted to join Eli Lilly & Company, current investors and Augustine’s exceptional team to develop these molecules until the clinical concept test and expand the number of indications.” values Clara Campàs, founder and managing partner of Asabys Partners.
Campàs joins the Board of Directors of Augustine Therapeutics and Isabel Jiménez, associate in Asabys and representative of Eli Lilly & Company, joins as Observer in the Council.
Related news:
Asabys Partners leads XRHealth $6 million funding (11 January 2024)
ICF invests €10m in Asabys Fund II, which already has 3 investees (18 September 2023)
Comments